-
Basilea Pharmaceutica used IDWeek 2026 in Washington D.C. to share new phase 3 and real world findings on fosmanogepix, Cresemba and Zevtera across pediatric and adult populations.
-
The concentration of pediatric access data, resistance profiling and post approval ceftobiprole experience points to a focus on broader usage and potential lifecycle management for Basilea's core anti infective portfolio.
-
We will now assess how this fresh clinical evidence package on Basilea Pharmaceutica's key anti infectives could reshape its broader investment narrative.
Scan beyond Basilea Pharmaceutica and compare its anti infective story with a curated 123 healthcare AI stocks targeting infection control, diagnostics, and treatment breakthroughs.
Basilea Pharmaceutica Investment Narrative Recap
To own Basilea Pharmaceutica you have to believe its anti infective focus can offset pressure from Cresemba losing exclusivity in the US and Europe at the end of 2027. IDWeek 2026 supports that belief only modestly. The new fosmanogepix, Cresemba and Zevtera data mainly refine the clinical story rather than altering near term revenue expectations.
The biggest near term swing factor still looks like execution on Zevtera's US rollout and partner driven hospital uptake. The main risk remains earnings and revenue forecasts that point to declines over the next three years, especially if late stage assets or lifecycle plans fail to replace Cresemba cash flows in time.
The fosmanogepix phase 3 and expanded access data at IDWeek 2026 is the most directly relevant update for Basilea Pharmaceutica. It touches the pipeline asset that could matter most once Cresemba patents start to expire. Evidence in difficult settings such as invasive mold infections and pediatric use helps investors judge clinical depth, not just trial headlines.
For catalysts, investors are likely to watch how these fosmanogepix readouts feed into regulatory dialogue and any future partnership or funding decisions. Execution risk shows up if further studies take longer, cost more, or generate mixed signals, which would leave the business leaning harder on Cresemba and Zevtera at a time when analysts already model declining revenue and earnings.
Basilea Pharmaceutica is modeled to generate CHF 203.3 million in revenue and CHF 12.3 million in earnings by 2029, based on analyst estimates that incorporate a yearly 6.3% decline in revenue and an earnings decrease of CHF 40.1 million from CHF 52.4 million today.
Uncover how Basilea Pharmaceutica's fair value indicates a 37% potential upside to its current price that may not last much longer.
Exploring Other Perspectives
One bullish twist on Basilea Pharmaceutica focuses on public funding rather than Cresemba or Zevtera. The most optimistic analysts lean on more than US$440m of committed non dilutive support and had pencilled in 2029 revenue of CHF 214.4 million and earnings of CHF 10.3 million. Those projections came before the fresh IDWeek 2026 data, so you may want to compare them with your own view and consider how opinions could shift as the new fosmanogepix evidence is digested.
Explore 2 other Basilea Pharmaceutica fair value estimates , including one that suggests up to 37% potential upside from the current price.
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
-
A great starting point for your Basilea Pharmaceutica research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
-
See our latest analysis for Basilea Pharmaceutica. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Basilea Pharmaceutica's overall financial health at a glance.
Looking For More Investment Ideas Beyond Basilea Pharmaceutica?
Once you have formed a view on Basilea Pharmaceutica, it can help to compare that thesis with other companies that match your preferred style, whether you care most about value, resilience, or future potential.
-
If you want potential mispricings with quality behind them, run your filters across a curated 195 high quality undervalued stocks that pairs healthy fundamentals with appealing valuations.
-
If capital preservation and steadier profiles matter more to you, start with a 223 resilient stocks with low risk scores that spots businesses with stronger risk scores and fewer financial red flags.
-
If balance sheet strength is non negotiable in your process, scan a list of solid balance sheet and fundamentals (207 results) that focuses on companies with cleaner debt profiles and solid financial footing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BSLN.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
